Endocrinologists praise FDA Avandia decision

While some critics have vigorously questioned an FDA panel's decision to let diabetes drug Avandia stay on the market, at least one physicians' group is happy about the news.  This week American Association of Clinical Endocrinologists (AACE) says while its members take the threat of increased cardiovascular disease seriously, it "welcomes" the panel's recommendation to keep Avandia on the market.

The AACE says it would like to see data from a group of long-term randomized studies currently underway, including the RECORD trial, ACCORD and BARI 2D studies. Meanwhile, its members will treat patients with Avandia (and related drug Actos), while working to manage side effects like weight gain, fluid retention and reduced bone mass.

To learn more about the group's position:
- read this AACE press release

Related Articles:
FDA panel votes to keep Avandia on the market. Report
Avandia risks exposed under deal to post data. Report
Avandia controversy sparks FDA criticism. Report
Glaxo: Avandia critic should pay for stock drop. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.